42. IDENTIFICATION OF BRAIN METASTASIS VULNERABILITIES USING METPLATFORM. (4th August 2020)

• Record Type: Journal Article
• Authors: Zhu, Lucía; Yebra, Natalia; Retana, Diana; Blanco-Aparicio, Carmen; Martínez, Sonia; Soffietti, Riccardo; Bertero, Luca; Cassoni, Paola; Weiss, Tobias; Muñoz, Javier; Manuel Sepúlveda, Juan; Pérez-Núñez, Ángel; Hernández-Laín, Aurelio; Toldos, Óscar; Caleiras, Eduardo; Nör, Carolina; Taylor, Michael D; Weller, Michael; Pastor, Joaquín; Valiente, Manuel
• Is Part Of: Neuro-oncology advances. Volume 2(2020)Supplement 2
• Page Start: ii8
• Page End: ii8
• Publication Date: 2020-08-04
• Subjects: 616.99481
• DOI: 10.1093/noajnl/vdaa073.030
• Languages: English
• ISSNs: 2632-2498

Abstract

Abstract: The diagnosis of brain metastasis involves high morbidity and mortality and remains an unmet clinical need in spite of being the most common tumor in the brain. Exclusion of these cancer patients from clinical trials is a major cause of their limited therapeutic options. In this study, we report a novel drug-screening platform (METPlatform) based on organotypic cultures which allows identifying effective anti-metastasis agents in the presence of the organ microenvironment. We have applied this approach to clinically relevant stages of brain metastasis using both experimental models and human tumor tissue (by performing patient-derived organotypic cultures). We identified heat shock protein 90 (HSP90) as a promising therapeutic target for brain metastasis. Debio-0932, a blood-brain barrier permeable HSP90 inhibitor, shows high potency against mouse and human brain metastases from melanoma, lung and breast adenocarcinoma with distinct oncogenomic profiles at clinically relevant stages of the disease, including a novel model of local relapse after neurosurgery. Furthermore, we have also used METPlatform to perform unbiased proteomics of brain metastases in situ. By applying this analysis to brain metastases treated with the chaperone inhibitor, we uncovered non-canonical clients of HSP90 as potential novel mediators of brain metastasis and actionable mechanisms of resistance driven by autophagy. Combined therapy using HSP90 and autophagy inhibitors showed synergistic effects compared to sublethal concentrations of each monotherapy, demonstrating the potential of METPlatform to design and test rationale combination therapies to target metastasis more effectively. In conclusion, our work validates METPlatform as a potent resource for metastasis research integrating drug-screening and unbiased omic approaches that is fully compatible with human samples and questions the rationale of excluding patients with brain metastasis from clinical trials. We envision that METPlatform will be established as a clinically relevant strategy to personalize the management of metastatic disease in the brain and elsewhere.